يُعرض باللغة الإنجليزية — الترجمة العربية قيد الإعداد
blog
آخر تحديث: 2019-07-22

(iPS Cells) Genetic Engineering Produces Immune Cells Without Triggering Rejection

S
فريق Medical Supporter
فريق تنسيق طبي دولي ومراجعة تحريرية
(iPS Cells) Genetic Engineering Produces Immune Cells Without Triggering Rejection

(iPS Cells) Genetic Engineering Produces Immune Cells Without Triggering Rejection

Medical Supporter — إشعار معلوماتي

هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.

يجب أن يقيّم أي خطة علاج محددة طبيب مرخّص في اليابان

On May 18, 2021, Professor Shin Kaneko's research team from the Kyoto University iPS Cell Research Institute published in a British scientific journal that killer T cells cultured from third-party iPS cells have been confirmed in mouse experiments to not only effectively suppress cancer but also to not trigger rejection reactions. This publication marks an achievement in the practical application of iPS cells for immune cell therapy.

Cancer treatment using transplanted T cells that attack foreign substances in the body — CAR-T therapy — has already been put into practical use and has attracted widespread attention. The main approach is to obtain T cells from the patient's blood, use genetic engineering to make those T cells more capable of recognizing cancer cells, and then reinfuse them into the body. However, the problem is that T cells have weak proliferative ability and treatment costs are very high. The research team therefore aimed to culture T cells from iPS cells, which can be produced in large quantities. However, there was concern that T cells cultured from third-party iPS cells might trigger rejection reactions.

Professor Kaneko's research team successfully used genetic engineering to cultivate T cells from iPS cells that can avoid being attacked by the patient's own immune cells and do not trigger rejection. Furthermore, mouse trials confirmed that compared to non-genetically modified T cells, the tumors shrank to nearly one-tenth the size, and no cancer cells were detected after 10 days. Professor Kaneko stated that T cells cultivated through genetic engineering (to reduce rejection reactions) can be used for more patients, and that in the future, iPS cells will be of great help in other transplant medical applications beyond just T cells.

Source: https://news.yahoo.co.jp/articles/79489782f69b49f0cfee0bc4a78e7b603ab49174

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟

نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.

المقر الرئيسي في فوكوكا: +81-92-409-5655
حاصل سابقًا على اعتماد رسمي، رقم B-066

Figure 1Figure 1

Figure 2Figure 2

Figure 3Figure 3

Figure 4Figure 4

قراءة ذات صلة